Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MIF | P14174 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16970628 | 1.00 | HCAR2 (0.43) | HCAR2ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL16970750 | 1.00 | HCAR2 (0.43) | HCAR2ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL14332190 | 0.88 | PTGS2 (0.48) | FFAR1 | |
| SCHEMBL4671825 | 0.80 | CHRNA7 (0.37) | LMNAALDH1A1KMT2AFFAR1ALOX5 | |
| SCHEMBL27868795 | 0.80 | CHRNA7 (0.37) | LMNAALDH1A1KMT2AFFAR1ALOX5 | |
| SCHEMBL7644979 | 0.79 | ADRA2A (0.41) | HCAR2ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL5519744 | 0.78 | THRB (0.42) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL2794041 | 0.78 | IDO1 (0.39) | LMNAKDM4EALDH1A1 | |
| SCHEMBL6141156 | 0.78 | ADRB2 (0.45) | LMNAHIF1AKDM4EALDH1A1KMT2A | |
| SCHEMBL8486238 | 0.78 | ADRA2A (0.38) | HCAR2ADRA2AADRA2CLMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112705-A1 | BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS | ELIMA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | claimed |
| EP-3053944-B1 | METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR | SHINETSU CHEMICAL CO (JP) | 2021-10-06 | — | — | EP | claimed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | claimed |
| EP-2758389-B1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | claimed |
| US-9394282-B2 | Pyrazole carboxamides as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-19 | — | — | US | claimed |
| US-9328099-B2 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | claimed |
| CN-102264708-B | Process for producing quinazoline derivative | SHIONOGI & CO | 2015-02-25 | — | — | CN | claimed |
| US-20140235641-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | INTERVET INC. | 2014-08-21 | — | — | US | claimed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | claimed |
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | claimed |
| EP-0091794-B1 | PROCESS FOR PREPARING 1.6-DISUBSTITUTED 2-AMINOBENZIMIDAZOLES | ELI LILLY AND COMPANY (US) | 1988-11-30 | — | — | EP | claimed |
| US-4434288-A | Preparation of substituted 1-thiazinyl or 1-thiazolyl-2-aminobenzimidazoles | ELI LILLY AND COMPANY (US) | 1984-02-28 | — | — | US | claimed |
| EP-0091794-A1 | Process for preparing 1.6-disubstituted 2-aminobenzimidazoles | ELI LILLY AND COMPANY (US) | 1983-10-19 | — | — | EP | claimed |
| EP-0023569-B1 | DERIVATIVES OF CARBOXYLIC ACIDS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1983-06-22 | — | — | EP | claimed |
| US-4292238-A | Alkylation of benzthiazole-azo-phenylamine dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-29 | — | — | US | claimed |
| US-4196125-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1980-04-01 | — | — | US | claimed |
| US-4118573-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | claimed |
| US-4018790-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | claimed |
| US-3991042-A | Basic azo dyestuffs containing a benzthiazole and a tetrahydroquinoline nucleus | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | claimed |
| US-3948877-A | POLYACRYLONITRILE, ACID MODIFIED POLYESTERS OR POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | HCAR2 915/4885ADRA2A 3573/4885ADRA2C 3263/4885 |
| US-20140235641-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | HCAR2 1294/4885ADRA2A 3541/4885ADRA2C 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.